Turkina, Anna, Vinogradova, Olga, Lomaia, Elza, Shatokhina, Evgeniya, Shukhov, Oleg, Chelysheva, Ekaterina, Shikhbabaeva, Dzhariyat, Nemchenko, Irina, Petrova, Anna, Bykova, Anastasiya, Siordiya, Nadiya, Shuvaev, Vasily, Mikhailov, Ilya, Novikov, Fedor, Shulgina, Veronika, Hochhaus, Andreas, Ottmann, Oliver  ORCID: https://orcid.org/0000-0001-9559-1330, Cortes, Jorge, Gale, Robert Peter and Chilov, Ghermes
2025.
Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.
Annals of Hematology
10.1007/s00277-025-06239-8
|
Preview |
PDF
- Published Version
Available under License Creative Commons Attribution. Download (1MB) | Preview |
Abstract
Vamotinib (PF-114) is a 3rd -generation, ATP-competitive oral tyrosine kinase inhibitor (TKI) active against wild-type and mutated BCR::ABL1 isoforms including BCR::ABL1T315I. We present final results of a phase-1 vamotinib dose-escalation study to identify maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) followed by expansion cohorts. 51 subjects with chronic myeloid leukaemia (CML) failing ≥ 1 2nd generation TKI or with BCR::ABL1T315I were enrolled. Subjects received vamotinib, 50–750 mg/d, continuously. Median exposure was 6 months (range, < 1–52 months). Median CML duration pre-study was 10 years (range, < 1–23 years). 27 subjects received ≥ 3 prior TKIs and 16 had BCR::ABL1T315I. The MTD was 600 mg with the Grade-3 psoriasis-like skin toxicity as the DLT. There were no vascular occlusive events nor deviations of ankle-brachial index. Complete haematologic response (CHR) was achieved in 14 of 30 subjects, major cytogenetic response (MCyR) in 14 of 44 subjects, complete cytogenetic response (CCyR) in 10 of 50 and major molecular response (MMR) in 7 of 51 subjects who did not have a CHR, MCyR, CCyR or MMR at enrollment. The best safety/efficacy dose was 300 mg with MCyR achieved in 6 of 7 subjects, CCyR in 5 of 9 and MMR in 4 of 9 subjects who did not have a MCyR, CCyR or MMR at enrollment. 5 of 16 subjects with BCR::ABL1T315I responded including 3 achieving a CHR, 3, a MCyR, and 1,a CCyR. 2 of 5 subjects failing ponatinib achieved a CHR. Vamotinib dose for further phase-3 study is 300 mg/d.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | In Press |
| Schools: | Schools > Medicine |
| Publisher: | Springer |
| ISSN: | 0939-5555 |
| Date of First Compliant Deposit: | 16 May 2025 |
| Date of Acceptance: | 30 January 2025 |
| Last Modified: | 20 May 2025 09:30 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/178340 |
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric